Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody
US12168054B2 · kind B2 · utility
0Cited by
8References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 18, 2018 |
| Grant date | Dec 17, 2024 |
| Priority date | — |
| Expiry date | Jan 10, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to a combination of an anti-CSF-1R antibody or anti-CSF-1 antibody or antigen binding fragment thereof or an inhibitor of CSF-1R activity and an HDAC inhibitor, e.g., entinostat, and methods of using the combination for administering to subjects in need thereof for the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.